Study Summary
This trial is investigating if a combination of drugs can effectively treat NSCLC.
- Soft Tissue Sarcoma
- Metastatic Soft Tissue Sarcoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: 30 months
Trial Safety
Phase-Based Safety
Side Effects for
Awards & Highlights
Trial Design
1 Treatment Group
Phase 1
1 of 1
Experimental Treatment
45 Total Participants · 1 Treatment Group
Primary Treatment: Trabectedin · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:- Gordon, Erlinda M., K. Kumar Sankhala, Neal Chawla, and Sant P. Chawla. 2016. “Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives”. Advances in Therapy. Springer Science and Business Media LLC. doi:10.1007/s12325-016-0344-3.
- Demetri, George D., Margaret von Mehren, Robin L. Jones, Martee L. Hensley, Scott M. Schuetze, Arthur Staddon, Mohammed Milhem, et al.. 2016. “Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial”. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO). doi:10.1200/jco.2015.62.4734.
- Hellman MD, Gettinger SN, Goldman JW, et al. CheckMate 012: Safety and efficacy of first-line (1L) NIVOLUMAB (nivo;N) and IPILIMUMAB (ipi;I) in advanced (adv) NSCLC. J Clin Oncol 2016, 34: (suppl; abstr 3001).
- Gordon EM, Sankhala KK, Stumpf N, Tseng WW, Chawla SP. Cancer immunotherapy with sequential administration of trabectedin and nivolumab in advanced soft tissue sarcoma. Presented at the Society of Immunotherapy for Cancer/ ITOC, Prague, Czech Republic, March, 2017
- Gordon EM, Sankhala KK, Chawla N, Chawla SP. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives. Adv Ther. 2016 Jul;33(7):1055-71. doi: 10.1007/s12325-016-0344-3. Epub 2016 May 27.
- 2017. "SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03138161.
Frequently Asked Questions
Could you illustrate the research conducted on Trabectedin to date?
"Currently, there are 779 active studies being conducted on Trabectedin with 88 of them in the third phase. These clinical trials are largely centered around Pittsburgh, Pennsylvania but can be found at 42897 centres worldwide." - Anonymous Online Contributor
How extensive is the current participant pool for this experiment?
"Correct. According to clinicaltrials.gov, the experimental trial commencing on April 13th 2017 is currently recruiting participants and requires 45 people from a single location for completion." - Anonymous Online Contributor
Are there any vacancies available within this research project?
"The data presented on clinicaltrials.gov indicates that this medical experiment is in its active recruitment phase, having initially been posted on April 13th 2017 and most recently updated on May 4th 2022." - Anonymous Online Contributor
What maladies is Trabectedin typically prescribed for?
"Trabectedin is typically used to treat inoperable melanoma, but it can also be prescribed for squamous cell carcinoma and a heightened risk of recurrence." - Anonymous Online Contributor